Orphan designation: bevacizumab Treatment of hereditary haemorrhagic telangiectasia, 16/12/2014 Positive
Orphan designation: alpelisib Treatment of PIK3CA related overgrowth spectrum, 26/03/2021 Positive
Orphan designation: Copper (64Cu) oxodotreotide Diagnosis of neuroendocrine neoplasms, 09/12/2022 Positive
New medicine for two types of pulmonary fibrosis
First medicine to treat rare uncontrolled growth of body tissues
First oral GLP-1 treatment for weight management
Overview of (invented) names reviewed in April 2026 by the Name Review Group (NRG) adopted at the CHMP meeting of 21 May 2026
Human medicines European public assessment report (EPAR): Deqtynet, copper (64Cu) oxodotreotide, Status: Opinion
Human medicines European public assessment report (EPAR): Ablymico, liraglutide, Status: Opinion
Human medicines European public assessment report (EPAR): Liraglutide STADA, liraglutide, Status: Opinion